Design and optimization of selective azaindole amide M1 positive allosteric modulators
Graphical abstract
Section snippets
Acknowledgements
We would like to acknowledge Anabella Villalobos, and Bruce Rogers for helpful discussions and Tim McNally, Sarah Neal, Katherine Brighty, Laurence Philippe, and HD Biosciences for technical assistance.
References and notes (25)
- (a)Sakamoto, H.; Sugimoto, T. WO 13129622 20130906,... et al.
ACS Med. Chem. Lett.
(2014) - et al.
ACS Chem. Neurosci.
(2010) - et al.
J. Comput. Aided Mol. Des.
(2009) - et al.
J. Med. Chem.
(2013)et al.J. Med. Chem.
(2014) Handb. Exp. Pharmacol.
(2012)- et al.
Neuropsychiatr. Dis. Treat.
(2014) - et al.
Arch. Neurol.
(1997)et al.Am. J. Psychiatry
(2008) - et al.
J. Neurosci.
(2009)et al.J. Med. Chem.
(2000)Proc. Natl. Acad. Sci. U.S.A.
(1996) Expert Opin. Investig. Drugs
(2000)- et al.
Nature
(2013)
Proc. Natl. Acad. Sci. U.S.A.
J. Biol. Chem.
Cited by (33)
Pyrido triazin-nucleus synthesis and theoretical studies: 2,3,6-trioxo-8-aryl-1,3,4,6-tetrahydro-]2H[pyrido]1,2-b] [1,2,4[triazin-7,9-dicarbonitryl derivatives
2021, Journal of Molecular StructureCitation Excerpt :For example, the IMHBs can stabilize the bioactive compound of a certain ligand. This decreases the translational and conformational entropy upon binding and lead to stronger connection [28–31] Several theoretical approaches can be applied to study HBs, for example atoms in molecules (AIM) methodology [32,33]. The AIM theory of Bader [34] was applied to analyze the topological properties of the bond critical point (BCP) of the hydrogen bond.
Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors
2020, Bioorganic and Medicinal Chemistry LettersAllosteric modulators targeting GPCRs
2019, GPCRs: Structure, Function, and Drug DiscoveryThe discovery of VU0486846: steep SAR from a series of M<inf>1</inf> PAMs based on a novel benzomorpholine core
2018, Bioorganic and Medicinal Chemistry LettersCitation Excerpt :M1 (muscarinic acetylcholine receptor subtype 1) positive allosteric modulators (PAMs) represent an exciting therapeutic strategy to treat multiple domains of cognitive dysfunction in CNS disorders such as schizophrenia and Alzheimer’s disease.1–5 However, the great potential of this target has been hindered, originally by nonselective orthosteric ligands (1),6 and then by potent ago-PAMs 2–5 (in cell lines (M1 PAM EC50s < 100 nM) and M1 agomist potency <1 μM) and native tissues) that proved to be cognitive disrupting and proconvulsive due to over stimulation of the M1 receptor (Fig. 1).7–12 Recently, we disclosed the first M1 PAM free from adverse events, VU6004256 (6),13 and with robust efficacy in NMDA receptor 1 (NR1) knock-down mice.14
Harnessing biosynthesis and quantitative NMR for late stage functionalization of lead molecules: Application to the M1 positive allosteric modulator (PAM) program
2018, Bioorganic and Medicinal Chemistry Letters